Back
About
Contineum Therapeutics, Inc., headquartered in San Diego, California, was established with the objective of developing small molecule treatments for neurological, inflammatory, and immunological disorders across major therapeutic areas.
The company is led by President, Chairman, and CEO Mr. Carmine Stengone, who joined in October 2018. He previously held the positions of President and CEO at Avelas Biosciences and Senior Vice President of Business Development at COI Pharmaceuticals.
Contineum’s primary drug candidate, PIPE-791, is currently in Phase 1 clinical trials targeting idiopathic pulmonary fibrosis and progressive multiple sclerosis.
The company aims to initiate Phase 1b trials to 'facilitate dosage determination for our forthcoming Phase 2 trials of PIPE-791 in IPF and progressive MS.'
Headquarters
10578 Science Center Drive, Suite 200 San Diego, California 92121
Team
|
Executive Officers: |
||||||
|
Carmine Stengone |
48 | Chief Executive Officer, President and Chairman of the Board | ||||
|
Peter T. Slover |
49 | Chief Financial Officer | ||||
|
Daniel S. Lorrain, Ph.D. |
55 | Chief Science Officer | ||||
|
Stephen L. Huhn, M.D. |
63 | Chief Medical Officer and Senior Vice President, Clinical Development |
Financial information
Main competitors
-
Genentech/Roche
-
Bristol-Myers Squibb
-
AbbVie
-
Horizon Therapeutics
-
Structure Therapeutics
-
Boehringer Ingelheim
-
United Therapeutics
-
Pliant Therapeutics
-
RedX Pharma
-
Endeavor Biomedicines
Underwriters
Goldman Sachs, Morgan Stanley, Stifel, RBC Capital Markets
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.